NSG533 / NSG 533 Exam 1 (Latest 2026/2027)
Advanced Pharmacology | Complete Guide with Questions and Verified Answers | 100% Correct
Wilkes University
Section 1: Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics
Q1: A nurse practitioner administers oral verapamil to a patient with hypertension. The patient achieves adequate blood
pressure control with the oral dose, but the effective dose is significantly higher than the IV dose required to achieve the
same effect. Which pharmacokinetic concept best explains this phenomenon?
A. Volume of distribution is higher with oral administration
B. First-pass metabolism reduces bioavailability of the oral dose **[CORRECT]**
C. Oral verapamil has lower protein binding than IV verapamil
D. Oral absorption is incomplete due to pH-dependent degradation in the stomach
Correct Answer: B
Rationale: Oral verapamil undergoes extensive first-pass hepatic metabolism before reaching the systemic circulation, resulting in a
bioavailability of only approximately 20-25%. This means a much higher oral dose is needed to achieve the same plasma concentration as an IV
dose that bypasses hepatic metabolism. First-pass effect is a critical pharmacokinetic consideration for drugs metabolized by CYP3A4 in the liver.
Volume of distribution (A) affects distribution, not bioavailability. Protein binding (C) does not differ significantly between routes. Verapamil
absorption is actually nearly complete but most is metabolized on first pass (D) (Wilkes NSG 533 Advanced Pharmacology, 2026-2027).
Q2: A patient who is an ultrarapid CYP2D6 metabolizer is prescribed codeine 60 mg for postoperative pain. The patient
reports severe respiratory depression and excessive sedation at the standard dose. What is the pharmacogenomic
explanation for this adverse reaction?
A. The patient has decreased CYP2D6 activity, leading to codeine accumulation
B. The patient has increased CYP2D6 activity, converting codeine to morphine more rapidly and producing toxic morphine
levels **[CORRECT]**
C. The patient has a CYP2C19 polymorphism that enhances codeine metabolism
D. The patient has impaired renal excretion of codeine's active metabolite
Correct Answer: B
Rationale: Codeine is a prodrug that requires CYP2D6-mediated O-demethylation to morphine, the active analgesic metabolite. Ultrarapid
CYP2D6 metabolizers (approximately 1-10% of populations depending on ethnicity) convert codeine to morphine at an accelerated rate,
producing unexpectedly high morphine levels that cause respiratory depression, sedation, and potentially death. This is a well-documented
pharmacogenomic safety concern, and the FDA has issued a black box warning against codeine use in ultrarapid metabolizers, particularly in
children post-tonsillectomy. Choice A describes poor metabolizers, who would experience no analgesic effect from codeine (Wilkes NSG 533,
2026-2027).
Q3: A 72-year-old patient with heart failure is prescribed digoxin. The nurse practitioner understands that digoxin has a
narrow therapeutic index. Which pharmacodynamic parameter defines the narrow therapeutic index?
A. The difference between the minimum effective concentration and the toxic concentration is small **[CORRECT]**
B. The drug has a very high volume of distribution
C. The drug is primarily metabolized by CYP3A4 with extensive first-pass metabolism
D. The drug has a very long elimination half-life requiring once-daily dosing
Correct Answer: A
Rationale: A narrow therapeutic index (NTI) means the difference between the therapeutic dose (or concentration) and the toxic dose is small,
requiring careful therapeutic drug monitoring. Digoxin has a therapeutic range of 0.5-2.0 ng/mL, with toxicity increasingly likely above 2.0
ng/mL. Other NTI drugs include lithium, warfarin, phenytoin, theophylline, and aminoglycosides. Volume of distribution (B) does not determine
therapeutic index. CYP3A4 metabolism (C) and long half-life (D) are pharmacokinetic properties unrelated to the therapeutic index definition
(Wilkes NSG 533, 2026-2027).
Q4: A drug has a volume of distribution (Vd) of 5 L in a 70-kg patient. The nurse practitioner interprets this value as
indicating that the drug is primarily distributed in which compartment?
A. Adipose tissue (highly lipophilic)
B. Total body water (hydrophilic, confined to plasma and extracellular fluid) **[CORRECT]**
, C. Intracellular fluid only
D. Bone tissue
Correct Answer: B
Rationale: A Vd of approximately 5 L (close to plasma volume) in a 70-kg patient indicates the drug is primarily confined to the vascular
compartment, suggesting high protein binding or large molecular size that limits tissue distribution. A Vd of 10-20 L suggests extracellular fluid
distribution. A Vd of 40-70 L (total body water) suggests hydrophilic distribution. A Vd significantly greater than total body water (>70 L,
sometimes hundreds of liters) indicates extensive tissue distribution, typically into adipose tissue for lipophilic drugs. Understanding Vd helps
predict loading doses and drug distribution patterns (Wilkes NSG 533, 2026-2027).
Q5: A patient is prescribed a drug that is a partial agonist at the benzodiazepine receptor. Compared to a full agonist at the
same receptor, the partial agonist will have which characteristic?
A. Higher efficacy and higher potency than the full agonist
B. Lower maximal efficacy but may have similar or higher affinity (potency) than the full agonist **[CORRECT]**
C. No clinical effect at any dose because it cannot fully activate the receptor
D. Identical dose-response curve to the full agonist
Correct Answer: B
Rationale: A partial agonist produces a submaximal response even when all receptors are occupied (lower Emax/efficacy) but may have similar
or even higher receptor affinity (potency/EC50) compared to a full agonist. In the presence of a full agonist, a partial agonist can act as a
competitive antagonist. Buprenorphine (partial mu-opioid agonist) and aripiprazole (partial D2 agonist) are clinical examples. Choice A is
incorrect because partial agonists by definition have lower maximal efficacy. Choice C is incorrect because partial agonists do produce clinical
effects, just not to the same maximum. Choice D is incorrect because the dose-response curves differ (Wilkes NSG 533, 2026-2027).
Q6: A patient with a known HLA-B*5701 allele is being evaluated for HIV treatment. Why is pharmacogenomic screening
for this allele critical before prescribing abacavir?
A. HLA-B*5701 is associated with abacavir resistance and treatment failure
B. HLA-B*5701 is associated with a severe hypersensitivity reaction to abacavir that can be fatal **[CORRECT]**
C. HLA-B*5701 increases the metabolism of abacavir requiring higher doses
D. HLA-B*5701 decreases the renal excretion of abacavir leading to toxicity
Correct Answer: B
Rationale: HLA-B*5701 is strongly associated with abacavir hypersensitivity syndrome, a multiorgan systemic reaction that can be fatal if
rechallenge occurs. The FDA mandates HLA-B*5701 screening before abacavir initiation, and the drug is contraindicated in patients who test
positive. Symptoms include fever, rash, GI symptoms, and respiratory involvement. This is a paradigm example of pharmacogenomic-guided
prescribing that prevents serious adverse drug reactions. It does not affect drug metabolism, resistance, or excretion (Wilkes NSG 533,
2026-2027).
Q7: A patient taking warfarin has genetic testing that reveals CYP2C9*3 and VKORC1 variants. The nurse practitioner
should expect which prescribing adjustment?
A. Increase the warfarin dose due to faster metabolism
B. Decrease the warfarin dose due to reduced metabolism and increased sensitivity to warfarin **[CORRECT]**
C. No dose adjustment is needed based on genotype
D. Switch to a direct oral anticoagulant regardless of genotype
Correct Answer: B
Rationale: CYP2C9*3 is a loss-of-function variant that reduces warfarin metabolism, and VKORC1 variants increase sensitivity to warfarin's
effect on vitamin K epoxide reductase. Together, these variants require significantly lower warfarin doses (often 30-50% lower) to achieve
therapeutic INR. Pharmacogenomic-guided warfarin dosing is an FDA-recognized application that reduces the risk of supratherapeutic INR and
bleeding during initiation. The FDA warfarin label includes pharmacogenomic dosing tables. This testing is most useful at treatment initiation
(Wilkes NSG 533, 2026-2027).
Q8: A patient with renal impairment has a decreased glomerular filtration rate. Which pharmacokinetic parameter is most
directly affected by reduced GFR?
A. First-pass metabolism
B. Renal clearance of drugs and active metabolites eliminated by the kidneys **[CORRECT]**
C. Hepatic phase I oxidation via CYP450 enzymes
D. Enteral absorption from the GI tract
Correct Answer: B
, Rationale: GFR is the primary determinant of renal clearance for drugs eliminated by glomerular filtration. Reduced GFR directly decreases
renal clearance, leading to drug accumulation and potential toxicity for renally eliminated drugs (e.g., aminoglycosides, vancomycin, lithium,
gabapentin, metformin, DOACs). First-pass metabolism (A) is a hepatic process. CYP450 metabolism (C) is hepatic. Absorption (D) is primarily a
GI process, though severe uremia can affect it indirectly. Dose adjustments based on GFR/creatinine clearance are essential for renally cleared
medications (Wilkes NSG 533, 2026-2027).
Q9: A patient is prescribed a highly protein-bound drug (98% bound to albumin). The nurse practitioner understands that
if another highly protein-bound drug is added that competes for the same binding sites, what is the expected clinical
consequence?
A. No significant clinical effect because the free fraction change is transient and self-correcting
B. A transient increase in free (unbound) drug concentration, potentially increasing pharmacologic effect and toxicity
**[CORRECT]**
C. A decrease in free drug concentration leading to loss of efficacy
D. Immediate and sustained toxicity due to displacement of the first drug
Correct Answer: B
Rationale: When two highly protein-bound drugs compete for the same binding sites, the displaced drug experiences a transient increase in free
(unbound) concentration, which can increase pharmacologic effect and potentially cause toxicity. However, this increase is usually transient
because the increased free drug is also more available for metabolism and excretion, establishing a new equilibrium. Clinical significance is
greatest for drugs with narrow therapeutic indices. While the effect is often transient (A is partially correct), it can be clinically important for NTI
drugs and requires monitoring (Wilkes NSG 533, 2026-2027).
Q10: A drug undergoes enterohepatic recirculation. The nurse practitioner understands that this process will have which
effect on the drug's pharmacokinetics?
A. Decrease the drug's half-life and duration of action
B. Prolong the drug's half-life and duration of action by reabsorbing the drug from the GI tract **[CORRECT]**
C. Have no effect on the drug's pharmacokinetic profile
D. Increase the first-pass metabolism of the drug
Correct Answer: B
Rationale: Enterohepatic recirculation occurs when a drug (or its conjugated metabolite) is secreted in bile into the intestine, then deconjugated
by intestinal bacteria and reabsorbed back into the systemic circulation. This process significantly prolongs the drug's half-life and duration of
action. Drugs undergoing enterohepatic recirculation include ethinyl estradiol, doxycycline, and valproic acid. This explains why some drugs
have very long half-lives despite efficient hepatic metabolism. It does not decrease half-life (A), and it is unrelated to first-pass metabolism (D)
(Wilkes NSG 533, 2026-2027).
Q11: A patient taking a CYP3A4 substrate medication consumes grapefruit juice daily. The nurse practitioner should
anticipate which effect?
A. Decreased drug levels due to CYP3A4 induction
B. Increased drug levels due to irreversible CYP3A4 inhibition in the intestinal wall, reducing first-pass metabolism
**[CORRECT]**
C. No effect because grapefruit juice only affects hepatic CYP3A4
D. Increased renal excretion of the drug
Correct Answer: B
Rationale: Grapefruit juice contains furanocoumarins that irreversibly inhibit intestinal CYP3A4, reducing presystemic (first-pass) metabolism
and increasing the oral bioavailability of CYP3A4 substrates. This effect is primarily intestinal rather than hepatic. Affected drugs include certain
statins (simvastatin, atorvastatin), calcium channel blockers, benzodiazepines, and buspirone. The inhibition can last up to 24-72 hours after
grapefruit juice consumption. It does not induce CYP3A4 (A) or increase renal excretion (D) (Wilkes NSG 533, 2026-2027).
Q12: A nurse practitioner is comparing two drugs with the following characteristics: Drug A has an EC50 of 5 mg and an
Emax of 100%. Drug B has an EC50 of 2 mg and an Emax of 60%. Which statement is correct?
A. Drug A is more potent and more efficacious than Drug B
B. Drug B is more potent but Drug A is more efficacious **[CORRECT]**
C. Drug B is more potent and more efficacious than Drug A
D. Drug A is more potent but Drug B is more efficacious
Correct Answer: B
Advanced Pharmacology | Complete Guide with Questions and Verified Answers | 100% Correct
Wilkes University
Section 1: Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics
Q1: A nurse practitioner administers oral verapamil to a patient with hypertension. The patient achieves adequate blood
pressure control with the oral dose, but the effective dose is significantly higher than the IV dose required to achieve the
same effect. Which pharmacokinetic concept best explains this phenomenon?
A. Volume of distribution is higher with oral administration
B. First-pass metabolism reduces bioavailability of the oral dose **[CORRECT]**
C. Oral verapamil has lower protein binding than IV verapamil
D. Oral absorption is incomplete due to pH-dependent degradation in the stomach
Correct Answer: B
Rationale: Oral verapamil undergoes extensive first-pass hepatic metabolism before reaching the systemic circulation, resulting in a
bioavailability of only approximately 20-25%. This means a much higher oral dose is needed to achieve the same plasma concentration as an IV
dose that bypasses hepatic metabolism. First-pass effect is a critical pharmacokinetic consideration for drugs metabolized by CYP3A4 in the liver.
Volume of distribution (A) affects distribution, not bioavailability. Protein binding (C) does not differ significantly between routes. Verapamil
absorption is actually nearly complete but most is metabolized on first pass (D) (Wilkes NSG 533 Advanced Pharmacology, 2026-2027).
Q2: A patient who is an ultrarapid CYP2D6 metabolizer is prescribed codeine 60 mg for postoperative pain. The patient
reports severe respiratory depression and excessive sedation at the standard dose. What is the pharmacogenomic
explanation for this adverse reaction?
A. The patient has decreased CYP2D6 activity, leading to codeine accumulation
B. The patient has increased CYP2D6 activity, converting codeine to morphine more rapidly and producing toxic morphine
levels **[CORRECT]**
C. The patient has a CYP2C19 polymorphism that enhances codeine metabolism
D. The patient has impaired renal excretion of codeine's active metabolite
Correct Answer: B
Rationale: Codeine is a prodrug that requires CYP2D6-mediated O-demethylation to morphine, the active analgesic metabolite. Ultrarapid
CYP2D6 metabolizers (approximately 1-10% of populations depending on ethnicity) convert codeine to morphine at an accelerated rate,
producing unexpectedly high morphine levels that cause respiratory depression, sedation, and potentially death. This is a well-documented
pharmacogenomic safety concern, and the FDA has issued a black box warning against codeine use in ultrarapid metabolizers, particularly in
children post-tonsillectomy. Choice A describes poor metabolizers, who would experience no analgesic effect from codeine (Wilkes NSG 533,
2026-2027).
Q3: A 72-year-old patient with heart failure is prescribed digoxin. The nurse practitioner understands that digoxin has a
narrow therapeutic index. Which pharmacodynamic parameter defines the narrow therapeutic index?
A. The difference between the minimum effective concentration and the toxic concentration is small **[CORRECT]**
B. The drug has a very high volume of distribution
C. The drug is primarily metabolized by CYP3A4 with extensive first-pass metabolism
D. The drug has a very long elimination half-life requiring once-daily dosing
Correct Answer: A
Rationale: A narrow therapeutic index (NTI) means the difference between the therapeutic dose (or concentration) and the toxic dose is small,
requiring careful therapeutic drug monitoring. Digoxin has a therapeutic range of 0.5-2.0 ng/mL, with toxicity increasingly likely above 2.0
ng/mL. Other NTI drugs include lithium, warfarin, phenytoin, theophylline, and aminoglycosides. Volume of distribution (B) does not determine
therapeutic index. CYP3A4 metabolism (C) and long half-life (D) are pharmacokinetic properties unrelated to the therapeutic index definition
(Wilkes NSG 533, 2026-2027).
Q4: A drug has a volume of distribution (Vd) of 5 L in a 70-kg patient. The nurse practitioner interprets this value as
indicating that the drug is primarily distributed in which compartment?
A. Adipose tissue (highly lipophilic)
B. Total body water (hydrophilic, confined to plasma and extracellular fluid) **[CORRECT]**
, C. Intracellular fluid only
D. Bone tissue
Correct Answer: B
Rationale: A Vd of approximately 5 L (close to plasma volume) in a 70-kg patient indicates the drug is primarily confined to the vascular
compartment, suggesting high protein binding or large molecular size that limits tissue distribution. A Vd of 10-20 L suggests extracellular fluid
distribution. A Vd of 40-70 L (total body water) suggests hydrophilic distribution. A Vd significantly greater than total body water (>70 L,
sometimes hundreds of liters) indicates extensive tissue distribution, typically into adipose tissue for lipophilic drugs. Understanding Vd helps
predict loading doses and drug distribution patterns (Wilkes NSG 533, 2026-2027).
Q5: A patient is prescribed a drug that is a partial agonist at the benzodiazepine receptor. Compared to a full agonist at the
same receptor, the partial agonist will have which characteristic?
A. Higher efficacy and higher potency than the full agonist
B. Lower maximal efficacy but may have similar or higher affinity (potency) than the full agonist **[CORRECT]**
C. No clinical effect at any dose because it cannot fully activate the receptor
D. Identical dose-response curve to the full agonist
Correct Answer: B
Rationale: A partial agonist produces a submaximal response even when all receptors are occupied (lower Emax/efficacy) but may have similar
or even higher receptor affinity (potency/EC50) compared to a full agonist. In the presence of a full agonist, a partial agonist can act as a
competitive antagonist. Buprenorphine (partial mu-opioid agonist) and aripiprazole (partial D2 agonist) are clinical examples. Choice A is
incorrect because partial agonists by definition have lower maximal efficacy. Choice C is incorrect because partial agonists do produce clinical
effects, just not to the same maximum. Choice D is incorrect because the dose-response curves differ (Wilkes NSG 533, 2026-2027).
Q6: A patient with a known HLA-B*5701 allele is being evaluated for HIV treatment. Why is pharmacogenomic screening
for this allele critical before prescribing abacavir?
A. HLA-B*5701 is associated with abacavir resistance and treatment failure
B. HLA-B*5701 is associated with a severe hypersensitivity reaction to abacavir that can be fatal **[CORRECT]**
C. HLA-B*5701 increases the metabolism of abacavir requiring higher doses
D. HLA-B*5701 decreases the renal excretion of abacavir leading to toxicity
Correct Answer: B
Rationale: HLA-B*5701 is strongly associated with abacavir hypersensitivity syndrome, a multiorgan systemic reaction that can be fatal if
rechallenge occurs. The FDA mandates HLA-B*5701 screening before abacavir initiation, and the drug is contraindicated in patients who test
positive. Symptoms include fever, rash, GI symptoms, and respiratory involvement. This is a paradigm example of pharmacogenomic-guided
prescribing that prevents serious adverse drug reactions. It does not affect drug metabolism, resistance, or excretion (Wilkes NSG 533,
2026-2027).
Q7: A patient taking warfarin has genetic testing that reveals CYP2C9*3 and VKORC1 variants. The nurse practitioner
should expect which prescribing adjustment?
A. Increase the warfarin dose due to faster metabolism
B. Decrease the warfarin dose due to reduced metabolism and increased sensitivity to warfarin **[CORRECT]**
C. No dose adjustment is needed based on genotype
D. Switch to a direct oral anticoagulant regardless of genotype
Correct Answer: B
Rationale: CYP2C9*3 is a loss-of-function variant that reduces warfarin metabolism, and VKORC1 variants increase sensitivity to warfarin's
effect on vitamin K epoxide reductase. Together, these variants require significantly lower warfarin doses (often 30-50% lower) to achieve
therapeutic INR. Pharmacogenomic-guided warfarin dosing is an FDA-recognized application that reduces the risk of supratherapeutic INR and
bleeding during initiation. The FDA warfarin label includes pharmacogenomic dosing tables. This testing is most useful at treatment initiation
(Wilkes NSG 533, 2026-2027).
Q8: A patient with renal impairment has a decreased glomerular filtration rate. Which pharmacokinetic parameter is most
directly affected by reduced GFR?
A. First-pass metabolism
B. Renal clearance of drugs and active metabolites eliminated by the kidneys **[CORRECT]**
C. Hepatic phase I oxidation via CYP450 enzymes
D. Enteral absorption from the GI tract
Correct Answer: B
, Rationale: GFR is the primary determinant of renal clearance for drugs eliminated by glomerular filtration. Reduced GFR directly decreases
renal clearance, leading to drug accumulation and potential toxicity for renally eliminated drugs (e.g., aminoglycosides, vancomycin, lithium,
gabapentin, metformin, DOACs). First-pass metabolism (A) is a hepatic process. CYP450 metabolism (C) is hepatic. Absorption (D) is primarily a
GI process, though severe uremia can affect it indirectly. Dose adjustments based on GFR/creatinine clearance are essential for renally cleared
medications (Wilkes NSG 533, 2026-2027).
Q9: A patient is prescribed a highly protein-bound drug (98% bound to albumin). The nurse practitioner understands that
if another highly protein-bound drug is added that competes for the same binding sites, what is the expected clinical
consequence?
A. No significant clinical effect because the free fraction change is transient and self-correcting
B. A transient increase in free (unbound) drug concentration, potentially increasing pharmacologic effect and toxicity
**[CORRECT]**
C. A decrease in free drug concentration leading to loss of efficacy
D. Immediate and sustained toxicity due to displacement of the first drug
Correct Answer: B
Rationale: When two highly protein-bound drugs compete for the same binding sites, the displaced drug experiences a transient increase in free
(unbound) concentration, which can increase pharmacologic effect and potentially cause toxicity. However, this increase is usually transient
because the increased free drug is also more available for metabolism and excretion, establishing a new equilibrium. Clinical significance is
greatest for drugs with narrow therapeutic indices. While the effect is often transient (A is partially correct), it can be clinically important for NTI
drugs and requires monitoring (Wilkes NSG 533, 2026-2027).
Q10: A drug undergoes enterohepatic recirculation. The nurse practitioner understands that this process will have which
effect on the drug's pharmacokinetics?
A. Decrease the drug's half-life and duration of action
B. Prolong the drug's half-life and duration of action by reabsorbing the drug from the GI tract **[CORRECT]**
C. Have no effect on the drug's pharmacokinetic profile
D. Increase the first-pass metabolism of the drug
Correct Answer: B
Rationale: Enterohepatic recirculation occurs when a drug (or its conjugated metabolite) is secreted in bile into the intestine, then deconjugated
by intestinal bacteria and reabsorbed back into the systemic circulation. This process significantly prolongs the drug's half-life and duration of
action. Drugs undergoing enterohepatic recirculation include ethinyl estradiol, doxycycline, and valproic acid. This explains why some drugs
have very long half-lives despite efficient hepatic metabolism. It does not decrease half-life (A), and it is unrelated to first-pass metabolism (D)
(Wilkes NSG 533, 2026-2027).
Q11: A patient taking a CYP3A4 substrate medication consumes grapefruit juice daily. The nurse practitioner should
anticipate which effect?
A. Decreased drug levels due to CYP3A4 induction
B. Increased drug levels due to irreversible CYP3A4 inhibition in the intestinal wall, reducing first-pass metabolism
**[CORRECT]**
C. No effect because grapefruit juice only affects hepatic CYP3A4
D. Increased renal excretion of the drug
Correct Answer: B
Rationale: Grapefruit juice contains furanocoumarins that irreversibly inhibit intestinal CYP3A4, reducing presystemic (first-pass) metabolism
and increasing the oral bioavailability of CYP3A4 substrates. This effect is primarily intestinal rather than hepatic. Affected drugs include certain
statins (simvastatin, atorvastatin), calcium channel blockers, benzodiazepines, and buspirone. The inhibition can last up to 24-72 hours after
grapefruit juice consumption. It does not induce CYP3A4 (A) or increase renal excretion (D) (Wilkes NSG 533, 2026-2027).
Q12: A nurse practitioner is comparing two drugs with the following characteristics: Drug A has an EC50 of 5 mg and an
Emax of 100%. Drug B has an EC50 of 2 mg and an Emax of 60%. Which statement is correct?
A. Drug A is more potent and more efficacious than Drug B
B. Drug B is more potent but Drug A is more efficacious **[CORRECT]**
C. Drug B is more potent and more efficacious than Drug A
D. Drug A is more potent but Drug B is more efficacious
Correct Answer: B
